Personally, I think this announcement could be considered price sensitive considering all the nuances in it. This is the result of a lot of hard work in the back ground and suggestive of a well considered plan coming together. Their ready to rock and roll
The change of emphasis to Neurological diseases and not just ALS/MND is noteworthy as well.
Ann: PharmAust makes Head of Manufacturing appointment, page-2
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.025(13.5%) |
Mkt cap ! $83.14M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 22.0¢ | 20.0¢ | $733.4K | 3.538M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 113800 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 240088 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
0.025 ( 13.5 %) |
||||
| Open | High | Low | Volume | ||
| 20.5¢ | 22.0¢ | 20.0¢ | 1388603 | ||
| Last updated 15.56pm 31/05/2024 ? | |||||
| PAA (ASX) Chart |